title: A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia.
abstract: There is clinical and biological evidence suggesting that patients with anger attacks, sudden spells of anger accompanied by intense autonomic activation, may represent a distinct psychopathological subgroup of patients with depressive disorders. We compared the prevalence of anger attacks in 168 outpatients with atypical depression or primary dysthymia with 38 normal subjects and tested the effect of treatment on anger attacks in a double-blind, placebo-controlled trial of sertraline versus imipramine. Patients were randomly assigned to sertraline (n = 56), imipramine (n = 52), or placebo (n = 60) and were administered the Anger Attacks Questionnaire before and after treatment. Depressed outpatients were significantly more likely to report anger attacks than controls. Anger attacks ceased in 53 percent of the patients receiving sertraline, 57 percent of those receiving imipramine, and 37 percent of those in the placebo group. Our findings support previous studies indicating that anger attacks are more prevalent among depressed outpatients than normals. Our results also suggest that sertraline and imipramine may be more effective than placebo in reducing the number of anger attacks following treatment although the differences were not statistically significant. Larger studies are needed to confirm our findings.
authors.affiliation: Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: M
authors.initials: M
authors.lastname: Fava
authors.forename: A A
authors.initials: AA
authors.lastname: Nierenberg
authors.forename: F M
authors.initials: FM
authors.lastname: Quitkin
authors.forename: S
authors.initials: S
authors.lastname: Zisook
authors.forename: T
authors.initials: T
authors.lastname: Pearlstein
authors.forename: A
authors.initials: A
authors.lastname: Stone
authors.forename: J F
authors.initials: JF
authors.lastname: Rosenbaum
mesh_terms: D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000786:Anger / Q000187:drug effects*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology*; D004311:Double-Blind Method; D019263:Dysthymic Disorder / Q000188:drug therapy* / Q000523:psychology*; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D020280:Sertraline
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D015057:1-Naphthylamine; D007099:Imipramine; D020280:Sertraline